Pompe disease drug combo shows Long-Term safety in phase 3 trial
NCT ID NCT04138277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the long-term safety of a combination therapy (ATB200 and AT2221) in 119 adults with late-onset Pompe disease who had completed a prior study. Participants received the drugs for an extended period, and researchers tracked side effects, walking distance, and lung function. The goal was to see if the treatment remains safe and helps maintain motor and breathing abilities over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cipaglucosidase alfa (enzyme replacement therapy) plus miglustat
- What this could lead to
- If successful, this could confirm a long-term treatment option that helps maintain walking ability and breathing function in adults with late-onset Pompe disease.
- What could go wrong
- This is an extension study, not a new test of effectiveness. Side effects like infusion reactions or serious adverse events may still occur, and not all patients may benefit equally.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POMPE DISEASE LATE-ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus Universitetshospital
Aarhus, Denmark
-
Alberta Children's Hospital, Heritage Medical Research Clinic
Calgary, Alberta, T3B 6A8, Canada
-
Billings Clinic
Billings, Montana, 59101, United States
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Centrum Medyczne Medyk
Rzeszów, Podkarpackie Voivodeship, 35-326, Poland
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Eginition Hospital
Athens, 11528, Greece
-
Emory Clinic
Atlanta, Georgia, 30322, United States
-
Erasmus MC
Rotterdam, 3015 GD, Netherlands
-
Friedrich-Baur Institut
München, 80336, Germany
-
Fukuoka University Hospital
Fukuoka, 814-0180, Japan
-
Hackensack University Medical Center
Hackensack, New Jersey, 07061, United States
-
Hokkaido University Hospital
Sapporo, 060 8648, Japan
-
Hospital Universitario Austral
Buenos Aires, B1629ODT, Argentina
-
Hospital de la Santa Creu I Sant Pau
Barcelona, Spain
-
Hôpital Pasteur 2
Nice, 06001, France
-
Hôpital Pierre Wertheimer
Bron, 69577, France
-
Hôpital Raymond Poincaré
Garches, 92380, France
-
Hôpital Salengro
Lille, 59037, France
-
Hôpital de la Timone
Marseille, 13385, France
-
IU Health Neuroscience Center
Indianapolis, Indiana, 46202, United States
-
Izumi City General Hospital
Osaka, 594 0073, Japan
-
Kagoshima University Hospital
Kagashima, 890-8520, Japan
-
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia, 22030, United States
-
McMaster University Medical Centre
Hamilton, Ontario, L8N 3Z5, Canada
-
Medizinische Universität Innsbruck
Innsbruck, A-6020, Austria
-
Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
NYU School of Medicine
New York, New York, 10017, United States
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Northwell Health
Great Neck, New York, 11021, United States
-
Pusan National University
Yangsan, Gyeongsangnam-do, 50612, South Korea
-
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2TH, United Kingdom
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Brisbane & Women's Hospital
Brisbane, Queensland, 4029, Australia
-
Royal Free Hospital NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
-
Salford Royal NHS Foundation Trust
Salford, M6 8HD, United Kingdom
-
Semmelweis University
Budapest, 1085, Hungary
-
The Jikei University Hospital
Tokyo, 105-8471, Japan
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
UOC di Neurologia e Malattie Neuromuscolari
Messina, 98124, Italy
-
UPMC Montefiore Clinical and Translational Research Center
Pittsburgh, Pennsylvania, 15213, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
Universitaria Federico II
Naples, 80131, Italy
-
University Clinical Centre of the Republic of Srpska
Banja Luka, The Republic of Srpska, 78000, Bosnia and Herzegovina
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Auckland
Auckland, 1142, New Zealand
-
University of California, Irvine
Irvine, California, 92868, United States
-
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio, 45219, United States
-
University of Florida Clinical Research Center
Gainesville, Florida, 32610, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pécs
Pécs, 7623, Hungary
-
University of Szeged
Szeged, 6725, Hungary
-
University of Utah
Salt Lake City, Utah, 84108, United States
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Universitätsklinikum Münster
Münster, 48149, Germany
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Westmead Hospital
Westmead, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hope for pompe patients: could a switch in enzyme therapy slow decline?
- Shocking muscles to move: new exercise hope for nerve disease patients
- New study monitors pregnancy in pompe disease patients
- One-Time gene therapy could change pompe disease treatment
- New drug cocktail aims to boost walking and breathing in pompe patients
- Pompe disease study aims to clear path for gene therapy